Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: a meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: a meta-analysis

Published:2023-04-03 Issue:1 Volume:45 Page:
ISSN:0886-022X
Container-title:Renal Failure
language:en
Short-container-title:Renal Failure

Author:

Guo Yong¹²³,Li Ling⁴,Hu Shanbiao¹²

Affiliation:

1. Department of Kidney Transplantation, The Second Xiangya Hospital of Central South University, Changsha, China

2. Clinical Research Center for Organ Transplantation in Hunan Province, Changsha, China

3. Department of Organ Procurement Organization, The Second Xiangya Hospital of Central South University, Changsha, China

4. Department of Urinary Surgery, The Second Xiangya Hospital of Central South University, Changsha, China

Publisher

Informa UK Limited

Subject

Nephrology,Critical Care and Intensive Care Medicine,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0886022X.2023.2179336

Reference43 articles.

1. Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives

2. The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

3. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride

4. Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile

5. Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical role of FGF21 in diabetic kidney disease: from energy metabolism to innate immunity;Frontiers in Immunology;2024-01-19

2. Fibroblast growth factor 21 predicts arteriovenous fistula functional patency loss and mortality in patients undergoing maintenance hemodialysis;Renal Failure;2024-01-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3